Skip to main content
. 2023 Mar 26;12(7):2503. doi: 10.3390/jcm12072503

Figure 2.

Figure 2

Outcomes in the initial (A) and maintenance period (B). The proportion of patients achieving clinical remission (HBI ≤ 4), clinical response (delta HBI ≥ 3) and steroid-free remission during the initial period (week 16–22) (A), and the proportion of patients achieving clinical remission, clinical response and steroid free remission during the maintenance period (week 52) (B); HBI: Harvey–Bradshaw index; UST: ustekinumab; anti-TNF: anti-tumor necrosis factor.